Gabelli Funds Trimmed Its Materion (MTRN) Holding; INNATE PHARMA MARSEILLE SHARES NOM CAT – (IPHYF) Shorts Raised By 58.99%

May 20, 2018 - By Adrian Erickson

Innate Pharma S.A. (OTCMKTS:IPHYF) Logo

Gabelli Funds Llc decreased Materion Corporation (MTRN) stake by 14.65% reported in 2017Q4 SEC filing. Gabelli Funds Llc sold 56,000 shares as Materion Corporation (MTRN)’s stock rose 4.76%. The Gabelli Funds Llc holds 326,300 shares with $15.86 million value, down from 382,300 last quarter. Materion Corporation now has $1.14 billion valuation. The stock increased 0.53% or $0.3 during the last trading session, reaching $56.55. About 73,615 shares traded. Materion Corporation (NYSE:MTRN) has risen 59.03% since May 20, 2017 and is uptrending. It has outperformed by 47.48% the S&P500.

INNATE PHARMA MARSEILLE SHARES NOM CAT – (OTCMKTS:IPHYF) had an increase of 58.99% in short interest. IPHYF’s SI was 229,900 shares in May as released by FINRA. Its up 58.99% from 144,600 shares previously. With 1,200 avg volume, 192 days are for INNATE PHARMA MARSEILLE SHARES NOM CAT – (OTCMKTS:IPHYF)’s short sellers to cover IPHYF’s short positions. The SI to INNATE PHARMA MARSEILLE SHARES NOM CAT -‘s float is 0.58%. It closed at $7.57 lastly. It is down 0.00% since May 20, 2017 and is . It has underperformed by 11.55% the S&P500.

Innate Pharma S.A., a clinical-stage biotechnology company, discovers, develops, and sells immunotherapies for cancer and inflammatory diseases in France. The company has market cap of $442.39 million. The firm offers Lirilumab , a human checkpoint inhibitor, which is in Phase I/II clinical trial for squamous cell carcinoma of the head and neck, as well as in Phase I and Phase II clinical trials in various combinations to treat solid and hematologic tumors; Monalizumab, an immune checkpoint inhibitor that is in Phase I/II clinical trial to treat various cancer indications, as well as in Phase I clinical trial for the treatment of solid tumors; and IPH4102, an anti-KIR3DL2 humanized antibody, which is in Phase I clinical trial for cutaneous T-cell lymphomas. It currently has negative earnings. It is also involved in developing IPH4301, a humanized anti-MICA/B therapeutic antibody to treat oncology; IPH52, an anti-CD39 antibody for immuno-oncology; IPH53, an anti-CD73 antibody for immuno-oncology; and IPH33, a monoclonal antibody program that targets Toll-like Receptor-3 receptor, which is an inducer of Type I IFN and pro-inflammatory cytokines; and IPH5401, a therapeutic antibody that binds and blocks C5a receptors expressed on subsets of myeloid-derived suppressor cells and neutrophils.

Gabelli Funds Llc increased Modern Media Acquisition Com stake by 129,378 shares to 296,178 valued at $2.91 million in 2017Q4. It also upped Oneok Inc New Com (NYSE:OKE) stake by 14,000 shares and now owns 903,000 shares. Alexion Pharmaceuticals Inc Co (NASDAQ:ALXN) was raised too.

More recent Materion Corporation (NYSE:MTRN) news were published by: Seekingalpha.com which released: “Materion’s (MTRN) CEO Jugal Vijayvargiya on Q1 2018 Results – Earnings Call Transcript” on April 29, 2018. Also Globenewswire.com published the news titled: “New Research: Key Drivers of Growth for Lincoln Electric, Cytosorbents, Materion, Fortune Brands Home & Security …” on May 04, 2018. Businesswire.com‘s news article titled: “Materion Corporation Increases Quarterly Cash Dividend” with publication date: May 02, 2018 was also an interesting one.

Investors sentiment decreased to 1.04 in 2017 Q4. Its down 0.14, from 1.18 in 2017Q3. It is negative, as 14 investors sold MTRN shares while 56 reduced holdings. 33 funds opened positions while 40 raised stakes. 17.68 million shares or 0.50% less from 17.77 million shares in 2017Q3 were reported. Mason Street Advsrs Ltd Llc owns 5,213 shares for 0.01% of their portfolio. Bnp Paribas Arbitrage invested 0% of its portfolio in Materion Corporation (NYSE:MTRN). Pnc Financial Serv Grp Inc Inc invested 0% of its portfolio in Materion Corporation (NYSE:MTRN). New York State Teachers Retirement Sys owns 70,342 shares or 0.01% of their US portfolio. James Investment has invested 0.06% in Materion Corporation (NYSE:MTRN). Pub Employees Retirement Of Ohio holds 3,268 shares or 0% of its portfolio. Keybank Association Oh holds 0% of its portfolio in Materion Corporation (NYSE:MTRN) for 8,344 shares. Teton Advisors has invested 0.79% in Materion Corporation (NYSE:MTRN). Voya Invest Mngmt Limited Liability Corporation reported 9,489 shares. First Personal Services accumulated 0.14% or 14,285 shares. Dimensional Fund Advisors LP has invested 0.03% of its portfolio in Materion Corporation (NYSE:MTRN). Wedge Cap Management L Limited Partnership Nc reported 28,525 shares or 0.01% of all its holdings. Piedmont Inv Advsrs Ltd Com holds 4,120 shares or 0% of its portfolio. Pillar Pacific Cap Mngmt Ltd Liability Corp has invested 0.04% in Materion Corporation (NYSE:MTRN). State Bank Of New York Mellon reported 0% of its portfolio in Materion Corporation (NYSE:MTRN).

Analysts await Materion Corporation (NYSE:MTRN) to report earnings on July, 26. They expect $0.51 EPS, up 21.43% or $0.09 from last year’s $0.42 per share. MTRN’s profit will be $10.30 million for 27.72 P/E if the $0.51 EPS becomes a reality. After $0.51 actual EPS reported by Materion Corporation for the previous quarter, Wall Street now forecasts 0.00% EPS growth.

Among 4 analysts covering Materion (NYSE:MTRN), 0 have Buy rating, 1 Sell and 3 Hold. Therefore 0 are positive. Materion had 13 analyst reports since August 27, 2015 according to SRatingsIntel. The firm has “Hold” rating by Jefferies given on Tuesday, January 9. As per Thursday, April 7, the company rating was downgraded by Stifel Nicolaus. The rating was maintained by Jefferies on Thursday, February 15 with “Hold”. The rating was maintained by Jefferies on Thursday, July 27 with “Hold”. Stifel Nicolaus upgraded the shares of MTRN in report on Thursday, August 27 to “Hold” rating. KeyBanc Capital Markets maintained Materion Corporation (NYSE:MTRN) on Thursday, October 12 with “Hold” rating. Jefferies maintained it with “Hold” rating and $3400 target in Friday, July 7 report. Jefferies maintained the stock with “Hold” rating in Friday, September 8 report. The rating was maintained by KeyBanc Capital Markets with “Hold” on Monday, November 13. The stock of Materion Corporation (NYSE:MTRN) has “Hold” rating given on Friday, June 2 by Jefferies.

Materion Corporation (NYSE:MTRN) Institutional Positions Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Posts

>